Paper Details

  1. Home
  2. Paper Details

Hyperbilirubinemia in atazanavir treated HIV-infected patients: the impact of the UGT1A1*28 allele.

Author: HatzakisAngelos, MaltezosEfstathios, PanagopoulosPeriklis, ParaskevisDimitrios

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Patients treated with atazanavir (ATV) boosted with ritonavir (rit) for HIV infection may experience elevated bilirubin levels. This side effect may be linked to genetic variations in the uridine diphosphate glucuronosyltransferase (UGT) enzyme, particularly the UGT1A1*28 variant. Pharmacogenetics/pharmacogenomics testing can help identify patients susceptible to this side effect and guide treatment decisions.
Paper Details　
Original Abstract of the Article :
Combination antiretroviral treatment (cART) has significantly improved the life expectancy of people living with HIV. The life-long nature of cART increases the risk of side effects, which in some cases may have been caused by specific genetic characteristics. Patients treated with atazanavir (ATV) ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488765/

データ提供：米国国立医学図書館（NLM）

Unraveling the Mystery of Hyperbilirubinemia in HIV Patients

This study investigates the impact of a specific gene variant on the occurrence of hyperbilirubinemia, a condition where bilirubin levels in the blood are elevated, in patients undergoing antiretroviral therapy for HIV. Think of it like a puzzle with pieces scattered across the vast desert of human genetics. The researchers sought to identify a specific genetic piece that contributes to the puzzle of hyperbilirubinemia.

UGT1A1*28: A Missing Piece of the Puzzle

The study reveals that the UGT1A1*28 allele, a variant in the UGT1A1 gene, is a key contributor to hyperbilirubinemia in HIV patients treated with atazanavir/ritonavir. This discovery is like finding a vital clue buried beneath the sand, providing a deeper understanding of the complex interplay between genetics and drug response.

Individualized Medicine: A Personalized Approach

This research highlights the importance of personalized medicine in treating HIV patients, taking into account individual genetic variations. By understanding the role of UGT1A1*28, doctors can tailor treatment plans to minimize the risk of hyperbilirubinemia and optimize patient outcomes.

Dr.Camel's Conclusion

The study emphasizes the significance of genetic variations in drug response, allowing for a more tailored and effective approach to HIV treatment. This research is a reminder that the human body is a complex desert of genetic information, and understanding its nuances is crucial for providing optimal care.

Date :
  1. Date Completed n.d.
  2. Date Revised 2020-10-01
Further Info :

Pubmed ID

28790862

DOI: Digital Object Identifier

PMC5488765

Related Literature

Article Analysis
・Side Effects of atazanavir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.